Clinical trial
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After…
NCT00312975 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00312975 |
|---|---|
| Title | Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Phase 2 Randomized, Non-Comparative Study Of CP-675,206 Or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy In Patients With Stage IIIB (With Effusion) Or Stage IV Non-Small Cell Lung Cancer That Has Responded Or Remained Stable |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung |
| Intervention type | Drug |
| Interventions | CP-675, 206, best supportive care |
| Enrollment | 90 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Feb 1, 2010 |
| First posted | Apr 11, 2006 |
| Last update posted | Jun 7, 2012 |
| Countries | Canada, Czechia, South Korea, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: